synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
== Computational approach == The basic idea behind reverse vaccinology is that an entire pathogenic genome can be screened using bioinformatics approaches to find genes. Some traits that the genes are monitored for, may indicate antigenicity and include genes that code for proteins with extracellular localization, signal peptides & B cell epitopes. Those genes are filtered for desirable attributes that would make good vaccine targets such as outer membrane proteins. Once the candidates are identified, they are produced synthetically and are screened in animal models of the infection.
Gabapentin enacarbil, sold under the brand name Horizant, among others, is an anticonvulsant and analgesic drug of the gabapentinoid class, and a prodrug to gabapentin. It was designed for increased oral bioavailability over gabapentin, and human trials showed it to produce extended release of gabapentin with almost twice the overall bioavailability, especially when taken with a fatty meal. Gabapentin enacarbil has passed human clinical trials for the treatment of restless legs syndrome, and initial results have shown it to be well tolerated and reasonably effective. Gabapentin enacarbil was denied approval by the US Food and Drug Administration (FDA) in February 2010, citing concerns about possible increased cancer risk shown by some animal studies. Similar concerns had been raised about gabapentin itself in the past, but were felt to be outweighed by its clinical utility as an anticonvulsant, whereas the treatment of restless legs syndrome was not seen to justify the same kind of risk. On 6 April 2011, Xenoport received FDA approval for Horizant (gabapentin enacarbil) for the treatment of moderate-to-severe restless legs syndrome. On 7 June 2012, the FDA approved Horizant for the treatment of postherpetic neuralgia in adults.
In most organisms non-coding genes (ncRNA) are transcribed as precursors that undergo further processing. In the case of ribosomal RNAs (rRNA), they are often transcribed as a pre-rRNA that contains one or more rRNAs. The pre-rRNA is cleaved and modified (2′-O-methylation and pseudouridine formation) at specific sites by approximately 150 different small nucleolus-restricted RNA species, called snoRNAs. SnoRNAs associate with proteins, forming snoRNPs. While snoRNA part basepair with the target RNA and thus position the modification at a precise site, the protein part performs the catalytical reaction. In eukaryotes, in particular a snoRNP called RNase, MRP cleaves the 45S pre-rRNA into the 28S, 5.8S, and 18S rRNAs. The rRNA and RNA processing factors form large aggregates called the nucleolus. In the case of transfer RNA (tRNA), for example, the 5′ sequence is removed by RNase P, whereas the 3′ end is removed by the tRNase Z enzyme and the non-templated 3′ CCA tail is added by a nucleotidyl transferase. In the case of micro RNA (miRNA), miRNAs are first transcribed as primary transcripts or pri-miRNA with a cap and poly-A tail and processed to short, 70-nucleotide stem-loop structures known as pre-miRNA in the cell nucleus by the enzymes Drosha and Pasha. After being exported, it is then processed to mature miRNAs in the cytoplasm by interaction with the endonuclease Dicer, which also initiates the formation of the RNA-induced silencing complex (RISC), composed of the Argonaute protein.
== Further reading == B.L. Karger, 2014, "Separation and Purification: Single-stage versus multistage processes" and "Separation and Purification: Separations Based on Equilibrium", Encyclopædia Britannica, see [1] and [2], accessed 12 May 2014. Gunt Hamburg, 2014, "Thermal Process Engineering: liquid–liquid extraction and solid-liquid extraction", see [3], accessed 12 May 2014. G.W. Stevens, T.C., Lo, & M. H. I. Baird, 2007, "Extraction, liquid–liquid", in Kirk-Othmer Encyclopedia of Chemical Technology, doi:10.1002/0471238961.120917211215.a01.pub2, accessed 12 May 2014. Colin Poole & Michael Cooke, 2000, "Extraction", in Encyclopedia of Separation Science, 10 Vols., ISBN 978-0-12-226770-3, see [4], accessed 12 May 2014. Sikdar, Cole, et al. Aqueous Two-Phase Extractions in Bioseparations: An Assessment. Biotechnology 9:254. 1991 Szlag, Giuliano. A Low-Cost Aqueous Two Phase System for Enzyme Extraction. Biotechnology Techniques 2:4:277. 1988 Dreyer, Kragl. Ionic Liquids for Aqueous Two-Phase Extraction and Stabilization of Enzymes. Biotechnology and Bioengineering. 99:6:1416. 2008 Boland. Aqueous Two-Phase Systems: Methods and Protocols. Pg 259-269 https://web.archive.org/web/20100702074135/http://ull.chemistry.uakron.edu/chemsep/extraction/ Topological Analysis of the Gibbs Energy Function (Liquid-Liquid Equilibrium Correlation Data). Including a Thermodynamic Review and a Graphical User Interface (GUI) for Surfaces/Tie-lines/Hessian matrix analysis - University of Alicante (Reyes-Labarta et al. 2015-18)
Sources: en.wikipedia.org
=== Convection === A type of natural convection that can be described by the Navier–Stokes equation is the Rayleigh–Bénard convection. It is one of the most commonly studied convection phenomena because of its analytical and experimental accessibility.
As of July 22, 2021, the position of the RSPCA is that Australian Merino sheep have not been ethically bred, as seen in their susceptibility to flystrike. They believe "any painful procedure to change the breech area should only be considered an interim, short-term solution that accompanies a breeding program that focusses on flystrike resistance and is carried out only where necessary to manage at-risk sheep".
As lieutenant governor in 2016, Newsom was the official proponent of Proposition 63. The ballot measure required a background check and California Department of Justice authorization to purchase ammunition, among other gun control regulations. In response to the 2019 mass shooting in Virginia Beach, Newsom called for nationwide background checks on people purchasing ammunition. Later that year, he responded to the Gilroy Garlic Festival shooting by stating his support for the Second Amendment and saying he would like national cooperation controlling "weapons of goddamned mass destruction". He also said, "These shootings overwhelmingly, almost exclusively, are males, boys, 'men'—I put in loose quotes. I do think that is missing in the national conversation." On June 10, 2021, Newsom called federal Judge Roger Benitez "a stone cold ideologue" and "a wholly owned subsidiary of the gun lobby of the National Rifle Association" after Benitez struck down California's statewide ban on assault weapons. While the ban remained in place as the state appealed the ruling, Newsom proposed legislation that would empower private citizens to enforce the ban after the United States Supreme Court declined to strike down the Texas Heartbeat Act, which empowers private citizens to report unauthorized abortions. In 2022, Newsom signed gun control bills passed by the California Legislature.
Believing that a deficiency in political theory was being filled by the entryist infiltration of the party by the Trotskyists (such as the Militant tendency), he thought the problem was better resolved by communist thinking from members of the CPGB. (He was later opposed to the expulsion of members of Militant.) In response, Denis Healey, Deputy Leader of the Labour Party, tried and failed to remove Galloway from the list of prospective parliamentary candidates. Healey lost his motion by 13 votes to five. Galloway once quipped that, to overcome a £1.5 million deficit which had arisen in Dundee's city budget, he, Ernie Ross, and leading councillors should be placed in the stocks in the city square: "We would allow people to throw buckets of water over us at 20p a time." In 1983, Galloway attempted to stand for the safe Labour seat of Rhondda after the Welsh Transport and General Workers' Union and the National Union of Miners had both nominated him to succeed Alec Jones, who had died. He hoped to be selected in the newly created seat of Dunfermline East, where no incumbent was standing. Galloway failed to be selected for either seat, with Rhondda selecting Allan Rogers, and Dunfermline East selecting future Chancellor of the Exchequer and later Prime Minister, Gordon Brown. Standing as a candidate for a place on the Labour Party National Executive Committee in 1986, in a large field of 18 candidates, Galloway finished in 16th place.
=== Fossil record === The earliest widely accepted animal fossils are rather modern-looking cnidarians, possibly from around 580 million years ago, although fossils from the Doushantuo Formation can only be dated approximately. The identification of some of these as embryos of animals has been contested, but other fossils from these rocks strongly resemble tubes and other mineralized structures made by corals. Their presence implies that the cnidarian and bilaterian lineages had already diverged. Although the Ediacaran fossil Charnia used to be classified as a jellyfish or sea pen, more recent study of growth patterns in Charnia and modern cnidarians has cast doubt on this hypothesis, leaving the Canadian polyp Haootia and the British Auroralumina as the only recognized cnidarian body fossils from the Ediacaran. Auroralumina is the earliest known animal predator. Few fossils of cnidarians without mineralized skeletons are known from more recent rocks, except in Lagerstätten that preserved soft-bodied animals. A few mineralized fossils that resemble corals have been found in rocks from the Cambrian period, and corals diversified in the Early Ordovician. These corals, which were wiped out in the Permian–Triassic extinction event about 252 million years ago, did not dominate reef construction since sponges and algae also played a major part. During the Mesozoic era, rudist bivalves were the main reef-builders, but they were wiped out in the Cretaceous–Paleogene extinction event 66 million years ago, and since then the main reef-builders have been scleractinian corals.
Sources: en.wikipedia.org
Irregularities were also reported on election day, with the election observation platform Vote62 receiving over 5,000 reports from citizens. In Chonburi Constituency 1, a large crowd gathered on 9 February to demand a recount following allegations of irregularities, including misplaced and improperly sealed ballot boxes, power outages during vote counting, vote total discrepancies, and vote tally sheets being found in a rubbish bin. The crowd remained guarding the ballot boxes overnight awaiting a decision by the Election Commission, which after a meeting asked for two days to gather and consider evidence before determining whether there would be a recount. A similar incident of crowds gathering to ask for a recount and guarding ballot boxes also occurred in Maha Sarakham Constituency 1. Following these and similar allegations, the People's Party formally requested recounts in 18 constituencies. One of its former MPs, Wiroj Lakkhanaadisorn, filed a police report against members of the Election Commission in Chonburi. The Pheu Thai Party also urged the Election Commission to investigate and address the concerns. Korn Chatikavanij, deputy leader of the Democrat Party, criticized the Election Commission, expressing disappointment that citizens were unable to feel trust in the election process. Pirapan Salirathavibhaga, the leader of the United Thai Nation Party, posted on his Facebook account demanding a nationwide recount.
==== Oil and gas ==== Residues from the oil and gas industry often contain radium and its decay products. The sulfate scale from an oil well can be radium rich, while the water, oil, and gas from a well often contain radon. The radon decays to form solid radioisotopes which form coatings on the inside of pipework. In an oil processing plant, the area of the plant where propane is processed is often one of the more contaminated areas of the plant as radon has a similar boiling point to propane. Radioactive elements are an industrial problem in some oil wells where workers operating in direct contact with the crude oil and brine can be exposed to doses having negative health effects. Due to the relatively high concentration of these elements in the brine, its disposal is also a technological challenge. Since the 1980s, in the United States, the brine is however exempt from the dangerous waste regulations and can be disposed of regardless of radioactive or toxic substances content.
Ultralente insulin was a long-acting form of medical insulin, but not a true analogue. It had an onset of 4 to 6 hours, a peak effect between 14 and 24 hours, and a duration of 28 to 36 hours. In the mid-2000s, ultralente insulin, along with lente insulin, was discontinued in the United States due to decreasing use in favor of NPH insulin and newer insulin products. By 2011, the U.S. Food and Drug Administration (FDA) had officially withdrawn approval for ultralente insulin products.
In 2023, Cambrex acquired the Waltham-headquartered chemical process development services provider, Snapdragon Chemistry. In 2024, Cambrex expanded Q1 Scientific with new state-of-the-art, temperature-controlled and monitored, stability storage facility in Durham, North Carolina. In 2025, Cambrex sold its large-scale drug product business unit to Noramco, including its two sites in Whippany, NJ and Mirabel, Quebec.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.